rs397516059
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000256.3(MYBPC3):c.551dupT(p.Lys185fs) variant causes a frameshift change. The variant allele was found at a frequency of 0.000000685 in 1,459,754 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: not found (cov: 32)
Exomes 𝑓: 6.9e-7 ( 0 hom. )
Consequence
MYBPC3
NM_000256.3 frameshift
NM_000256.3 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 5.22
Genes affected
MYBPC3 (HGNC:7551): (myosin binding protein C3) MYBPC3 encodes the cardiac isoform of myosin-binding protein C. Myosin-binding protein C is a myosin-associated protein found in the cross-bridge-bearing zone (C region) of A bands in striated muscle. MYBPC3 is expressed exclusively in heart muscle and is a key regulator of cardiac contraction. Mutations in this gene are a frequent cause of familial hypertrophic cardiomyopathy. [provided by RefSeq, May 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 11-47349876-C-CA is Pathogenic according to our data. Variant chr11-47349876-C-CA is described in ClinVar as [Pathogenic]. Clinvar id is 42771.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| MYBPC3 | ENST00000545968.6 | c.551dupT | p.Lys185fs | frameshift_variant | 5/35 | 5 | NM_000256.3 | ENSP00000442795.1 | ||
| MYBPC3 | ENST00000399249.6 | c.551dupT | p.Lys185fs | frameshift_variant | 5/34 | 5 | ENSP00000382193.2 | |||
| MYBPC3 | ENST00000544791.1 | n.551dupT | non_coding_transcript_exon_variant | 5/27 | 5 | ENSP00000444259.1 |
Frequencies
GnomAD3 genomes
GnomAD3 genomes
Cov.:
32
GnomAD4 exome AF: 6.85e-7 AC: 1AN: 1459754Hom.: 0 Cov.: 31 AF XY: 0.00000138 AC XY: 1AN XY: 726036
GnomAD4 exome
AF:
AC:
1
AN:
1459754
Hom.:
Cov.:
31
AF XY:
AC XY:
1
AN XY:
726036
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome
GnomAD4 genome
Cov.:
32
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:7
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:2
| Likely pathogenic, no assertion criteria provided | clinical testing | Stanford Center for Inherited Cardiovascular Disease, Stanford University | Jun 19, 2013 | Note this variant was found in clinical genetic testing performed by one or more labs who may also submit to ClinVar. Thus any internal case data may overlap with the internal case data of other labs. The interpretation reviewed below is that of the Stanford Center for Inherited Cardiovascular Disease. MYBPC3 p.Lys185GlufsX56 Based on the data reviewed below we consider this variant as likely disease-causing, based on the type of variant and gene. This variant is located in exon 5 of the MYPBC3 gene. This is a frameshift variant. The c.551dupT variant causes a shift in the reading frame at codon Lysine185, changing it to an Glutamic acid and creates a premature Stop codon at position 56 of the new reading frame. The variant is expected to either cause a truncated protein or a completely absent protein due to nonsense-mediated mRNA decay. This variant is novel. While this specific variant is novel, many other frameshift and null variants have been identified in MYBPC3 in association with cardiomyopathy (ex. p.Trp792fs, p.Pro794fs, p.Lys1065fs, p.Cys1202fs, p.Pro1208fs, p.Trp1098ter, p.Glu1096ter, p.Cys1124ter, p.Gln1233ter). The variant is not currently listed in the NHLBI Exome Sequencing Project dataset, which includes variant calls on ~6.500 Caucasian and African American individuals (as of 1/3/14). This variant has not been reported in dbSNP or 1000Genomes. GeneDx did not report control data. - |
| Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Dec 17, 2024 | Identified in several patients with HCM referred for genetic testing at GeneDx and in the published literature (PMID: 25611685, 27532257, 37652022); Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 27532257, 25611685, 37652022) - |
Hypertrophic cardiomyopathy Pathogenic:2
| Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Aug 13, 2015 | The p.Lys185fs variant in MYBPC3 has been previously identified by our laborator y in three Caucasian adults with HCM. It has not been identified in large popula tion studies, though the ability of these studies to detect indels accurately ma y be limited. This variant is predicted to cause a frameshift, which alters the protein?s amino acid sequence beginning at position 185 and leads to a premature termination codon 56 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Heterozygous loss-of-function of the M YBPC3 gene is an established disease mechanism in individuals with HCM. In summa ry, this variant meets our criteria to be classified as pathogenic for HCM in an autosomal dominant manner (http://www.partners.org/personalizedmedicine/LMM) ba sed upon the predicted impact of the variant. - |
| Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 17, 2023 | This sequence change creates a premature translational stop signal (p.Lys185Glufs*56) in the MYBPC3 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MYBPC3 are known to be pathogenic (PMID: 19574547). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with MYBPC3-related conditions. ClinVar contains an entry for this variant (Variation ID: 42771). For these reasons, this variant has been classified as Pathogenic. - |
Cardiomyopathy Pathogenic:1
| Pathogenic, criteria provided, single submitter | clinical testing | CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario | Nov 10, 2021 | - - |
Hypertrophic cardiomyopathy 4 Pathogenic:1
| Pathogenic, criteria provided, single submitter | clinical testing | Molecular Diagnostic Laboratory for Inherited Cardiovascular Disease, Montreal Heart Institute | Apr 26, 2016 | p.Lys185GlufsTer55 (CTGAAG>CT{T}GAAG) : c.551dupT in exon 5 of the MYBPC3 gene (NM_000256.3). The variant Lys185GlufsTer55 (p.K185EfsX55) in the MYBPC3 gene has not been reported to our knowledge. However, it was observed in more than ten (10) unrelated families tested for HCM by the Molecular Diagnostics Laboratory of the Montreal Heart Institute. It meets the following criteria of pathogenicity of the ACMG : PVS1 : The duplication of a thymidine at position 551 causes a change in the reading frame for 55 amino acids and leads to a stop codon resulting in a shortened protein of 81%. This variant is expected to result in an abnormal product : a truncated protein or loss of protein production from this allele through nonsense-mediated accelerated decay of the mRNA. PM2 :Lys185GlufsTer55 was not reported in ExAC database (more than 120,000 alleles) and was not observed in the populations of the 1000 Genome Project (more than 5000 individuals) neither in the populations of European and African American ancestry in the NHLBI Exome Sequencing Project (more than 6500 individuals). This means it is not a common benign variant in these populations. PP5 :The variant was the subject of two submissions in ClinVar: both in pathogenic category. In summary, Lys185GlufsTer55 in the MYBPC3 gene combines a very strong criteria of pathogenicity, a moderate criteria and a supporting criteria. It is interpreted as pathogenic variant. - |
Cardiovascular phenotype Pathogenic:1
| Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 08, 2020 | The c.551dupT pathogenic mutation, located in coding exon 5 of the MYBPC3 gene, results from a duplication of T at nucleotide position 551, causing a translational frameshift with a predicted alternate stop codon (p.K185Efs*56). This variant has been detected in a cohort referred for hypertrophic cardiomyopathy genetic testing (Walsh R et al. Genet Med. 2017 02;19:192-203). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at